belotero-dermal-filler.jpg Merz Pharmaceuticals has announced that the Food and Drug Administration of the United States has formally accepted for review their pre-market approval application for their dermal filler, Belotero Balance, which was first introduced in Germany in 2005. This acceptance begins the application review process. It also signifies the beginning of Merz Pharmaceutical's presence in the American aesthetics market.

Product Highlights
a. This is a hyaluronic acid based monophasic gel dermal filler.
b. This filler uses a cohesive polydensified matrix (CPM) technology.
c. It is awaiting FDA approval for injection into mid-to-deep dermis for correction of moderate to severe wrinkles and folds.
d. It is cost effective and easy-to-use with low implanting pain.
e. It integrates homogenously into the skin and results in a smooth, natural, revitalized appearance.
f. CPM technology is safe and causes an immediate long-lasting lifting effect.
g. It does not leave any requirement for post-correction.
h. This product is already approved for aesthetic use in the United Kingdom, Italy, Russia, Austria and Switzerland.